{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:28:38Z","timestamp":1794216518981,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008361","name":"Danish Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jneuroim.2026.579097","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:12:42Z","timestamp":1788970362000},"page":"579097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dipeptidyl peptidase-4 inhibitors and risk of multiple sclerosis: A Danish nationwide matched case-control study"],"prefix":"10.1016","volume":"421","author":[{"given":"Philip Ahle","family":"Erichsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida M.","family":"Heerfordt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Framke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jneuroim.2026.579097_bb0005","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"issue":"23","key":"10.1016\/j.jneuroim.2026.579097_bb0010","doi-asserted-by":"crossref","first-page":"16786","DOI":"10.3390\/ijms242316786","article-title":"From molecular insights to clinical perspectives in drug-associated bullous pemphigoid","volume":"24","author":"De Nicolas-Ruanes","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.jneuroim.2026.579097_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250302","article-title":"Immunomodulatory activity of dipeptidyl peptidase-4 inhibitors in immune-related diseases","volume":"53","author":"Drakul","year":"2023","journal-title":"Eur. J. Immunol."},{"issue":"S2","key":"10.1016\/j.jneuroim.2026.579097_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ene.12798","article-title":"A basic overview of multiple sclerosis immunopathology","volume":"22","author":"Grigoriadis","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579097_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106299","article-title":"Allopurinol use and risk of multiple sclerosis","volume":"94","author":"Heerfordt","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579097_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s44197-025-00353-6","article-title":"Epidemiology of multiple sclerosis: global, regional, national and sub-National-Level Estimates and future projections","volume":"15","author":"Khan","year":"2025","journal-title":"J. Epidemiol. Glob. Health."},{"issue":"6","key":"10.1016\/j.jneuroim.2026.579097_bb0035","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bjd.15405","article-title":"Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid","volume":"176","author":"Kibsgaard","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"11","key":"10.1016\/j.jneuroim.2026.579097_bb0040","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1136\/annrheumdis-2014-205216","article-title":"Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study","volume":"74","author":"Kim","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579097_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12781","article-title":"Cut to the chase: a review of CD26\/dipeptidyl peptidase-4\u2019s (DPP4) entanglement in the immune system","volume":"185","author":"Klemann","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579097_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00403-021-02317-9","article-title":"Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation","volume":"315","author":"Kridin","year":"2022","journal-title":"Arch. Dermatol. Res."},{"issue":"12","key":"10.1016\/j.jneuroim.2026.579097_bb0055","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jdv.13660","article-title":"Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis","volume":"30","author":"Lai","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579097_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1921","article-title":"The Danish multiple sclerosis registry","volume":"11","author":"Magyari","year":"2021","journal-title":"Brain Behav."},{"issue":"15","key":"10.1016\/j.jneuroim.2026.579097_bb0065","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3390\/ijerph16152720","article-title":"The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect","volume":"16","author":"Makrilakis","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579097_bb0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"7_suppl","key":"10.1016\/j.jneuroim.2026.579097_bb0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish civil registration system","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand. J. Public Health"},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579097_bb0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-pathol-052920-040318","article-title":"The immune response in multiple sclerosis","volume":"17","author":"Rodr\u00edguez Mur\u00faa","year":"2022","journal-title":"Annu. Rev. Pathol.: Mech. Dis."},{"issue":"8","key":"10.1016\/j.jneuroim.2026.579097_bb0085","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/bcp.13955","article-title":"Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: a nationwide population-based cohort study","volume":"85","author":"Seong","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jneuroim.2026.579097_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107503","article-title":"Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions","volume":"209","author":"Shao","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jneuroim.2026.579097_bb0095","series-title":"Municipality Groups V1","volume":"2018","author":"Statistics Denmark","year":"2018"},{"issue":"2","key":"10.1016\/j.jneuroim.2026.579097_bb0100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.clim.2013.11.011","article-title":"Low DPP4 expression and activity in multiple sclerosis","volume":"150","author":"Tejera-Alhambra","year":"2014","journal-title":"Clin. Immunol."},{"issue":"7_suppl","key":"10.1016\/j.jneuroim.2026.579097_bb0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry","volume":"39","author":"Wallach Kildemoes","year":"2011","journal-title":"Scand. J. Public Health"},{"issue":"14","key":"10.1016\/j.jneuroim.2026.579097_bb0110","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.jneuroim.2026.579097_bb0120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2337\/dc24-1699","article-title":"Incidence and risk factors of diagnosed young-adult-onset type 2 diabetes in the U.S.: the National Health Interview Survey 2016\u20132022","volume":"48","author":"Xu","year":"2025","journal-title":"Diabetes Care"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826002468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826002468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:17:00Z","timestamp":1794215820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572826002468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":23,"alternative-id":["S0165572826002468"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579097","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dipeptidyl peptidase-4 inhibitors and risk of multiple sclerosis: A Danish nationwide matched case-control study","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"579097"}}